Indian Journal of Clinical and Experimental Ophthalmology

Print ISSN: 2395-1443

Online ISSN: 2395-1451

CODEN : IJCEKF

Indian Journal of Clinical and Experimental Ophthalmology (IJCEO) is open access, a peer-reviewed medical journal, published quarterly, online, and in print, by the  Innovative Education and Scientific Research Foundation (IESRF) since 2015. To fulfill our aim of rapid dissemination of knowledge, we publish articles ‘Ahead of Print’ on acceptance. In addition, the journal allows free more...


  • Article highlights
  • Article tables
  • Article images

Article statistics

Viewed: 97

PDF Downloaded: 45


Kumar, Razali, and Hitam: Hydroxychloroquine retinal toxicity- Can we do better with SD-OCT?


Introduction

Hydroxychloroquine is an immunomodulator drug often used as a disease-modifying antirheumatic drug (DMARDs) and acts by inhibition and modulation of immune responses. Hydroxychloroquine also used in many conditions including diabetes mellitus, heart disease, graft-versus-host disease, adjunctive cancer therapy, systemic vasculitis and Coronavirus Disease 2019 (COVID-19).1, 2, 3, 4

Hydroxychloroquine retinal toxicity is a serious condition with potential retinal damage and has a higher prevalence than previously documented.5 The mechanism involved binding of hydroxychloroquine to the melanin of retinal pigmented epithelium, inhibits its activity over a prolonged period,6 causing thinning to both the inner and outer retina.7 Other mechanism is retinal vasculitis with retinal microinfarcts initiating the RNFL and macular thinning (inner retina), and arteriolar narrowing and disc pallor in higher concentration.8 Rare mechanism with early toxicity occurred with genetic predisposition to hydroxychloroquine9 and polymorphisms in the cytochrome P450 gene that increased hydroxychloroquine blood concentration.10

Visual acuity is usually good until the development of severe toxicity, so any efficient screening should detect structural changes (retina damage) before functional deterioration. Spectral Domain Optical Coherence Tomography (SD-OCT) is an important addition for early detection of hydroxychloroquine toxicity. The SD-OCT cross-section images at mild toxicity are subtle or unremarkable. Moderate toxicity has a distinctive discontinuity of the photoreceptor inner segment/outer segment.11 With time, the outer nuclear layer thinning occurred.12 However, the outer retinal thickness remains normal despite the destruction of outer segment photoreceptors creating the “flying saucer’’ or sombrero sign.13 Severe toxicity includes disruption of the outer retina and RPE.

The recommended dose of hydroxychloroquine, ophthalmology baseline, and follow-ups plus the screening tools changes over the years was summarized in (Table 1). The paradigm shift of these guidelines tally with discoveries of increased prevalence and the reversible retinal changes with early detection and intervention using SD-OCT. The current recommended dose is 5mg/kg real body weight per day with a baseline SD-OCT and re-imaging at 5 years of hydroxychloroquine usage to most patients classified as a low-risk group.5

Many cross-sectional studies using SD-OCT have shown earlier retina damages, but none had measured continuously from the beginning of hydroxychloroquine usage. Thus, the purpose of this pilot prospective cohort study is to evaluate the sequential changes of retina thickness in patients newly treated with hydroxychloroquine using the latest guideline recommendations.

Materials and Methods

This study was conducted after obtaining approvals from the Ethical Committee of Universiti Sains Malaysia and the Ministry of Health of Malaysia per the Declaration of Helsinki for Human Research (USM/JEPeM/ l6060209 and NMRR-16-116-28987 (IIR)). The sample size was calculated using closest studies using G*Power version 3.1.9.2 for Windows available at http://www.gpower.hhu.de We have summarized the methodology in (Figure 1). Written consent was obtained from all patients.

Figure 1

Methodology of the study

https://typeset-prod-media-server.s3.amazonaws.com/article_uploads/16fa3341-6bd1-415b-a6aa-f9efc7590d26/image/7dcee1f2-d7d4-433d-add7-ae55dc56080d-uimage.png

These patients underwent complete ocular and systemic history with the full ocular examination via slit lamp biomicroscope (Topcon Corp, Japan) and Volk Super 66 stereo fundus lens and then OCT macula and Optic disc (Cirrus-HD OCT 4000 software version 5.0, Carl Zeiss Meditec, Inc, Dublin, CA) pre, and 6 months of hydroxychloroquine treatment. At 3 months of hydroxychloroquine treatment, only OCT measurements were obtained in patients except for any visual symptoms where a complete ocular examination was conducted. Only tests that yielded signal strength of at least 6 and above were taken for interpretation to ensure the accuracy of the result.

A total of 33 patients were recruited. Two patients did not fulfill the selection criteria and five patients were lost to follow up. 26 patients were studied as per the protocol and included for analysis. Data collection and analysis were performed using the Statistical Package for the Social Sciences (SPSS) version 24 (SPSS, Chicago, IL, USA). Descriptive statistics were used to summarize the basic characteristics of the patients. Normally distributed data were expressed as mean ± standard deviation. All values were tested for normal distribution in all groups. Repeated Measured ANOVA test used to compare the macular thickness and RNFL thickness pre, 3 months, and 6 months. A P value of less than 0.05 (P<0.05) was considered significant.

Results

Demographic data

We summarize demographic characteristics of the patients in (Table 2). Our patients were young with a mean age of 33.92 years. Females were predominant (76.9%). Malay race was the most (50%). SLE is the most common disease (57.7%). Generally, all the patients having good visual acuity and vision remain unchanged for the period of this study except the 3 patients with 6/12 visual acuity who improved with glasses prescription and/or artificial tears.

Table 1

Paradigm shifts in the recommendation of guidelines on hydroxychloroquine screening

RCOphth, 199314

RCOphth, 199815

AAO, 200216

RCOphth, 200417

RCOphth, 200918

AAO, 201119

AAO, 201720

RCOphth, 201821

Recommended dosage

6.5 mg/kg lean weight

6.5 mg/kg lean weight

6.5 mg/kg lean weight

6.5 mg/kg lean weight

6.5 mg/kg lean weight

6.5 mg/kg lean weight

5.0 mg/kg

real weight

5.0 mg/kg

real weight

Baseline screening

Recommended

ophthalmology examination when starting, with VA, fundus and HVF 10-2

Respective discipline monitor with renal and liver function, history of visual symptoms, near VA

Referral to ophthalmology if vision derangement or reduced VA

Assessment should be done by an ophthalmologist within 1 year, of starting therapy

High risk:

  • More than 5 years of usage

  • High dosage.

  • High body fat level.

  • Kidney, liver, or retinal diseases.

  • More than 60 years old.Low risk:

  • Less than 5 years of usage

Respective disciplines monitoring

Suggested for ophthalmology assessment

Referral to ophthalmology if vision derangement or reduced VA

Respective disciplines monitoring with

Amsler Chart (preferably red on black) and/or HVF 10-2

Referral to an optometrist if any visual complains

Suggested for ophthalmology assessment

Advised for an ophthalmologist assessment when starting

High and Low risk as AAO 2002

Assessment should be done by an ophthalmologist within 1 year, of starting therapy

Major toxicity factors:

  • Daily Dose (more than 5mg/kg)

  • Duration of use (more than 5 years).

  • Renal disease (subnormal glomerular filtration rate)

  • Concomitant drugs (Tamoxifen).

  • Retina and Macular diseases

Lesser toxicity factors:

  • Age (Elderly)

  • Liver Disease

  • Genetic Factors

Assessment should be done by an ophthalmologist within six months, but not more than 12 months, of starting therapy with a colour retinal photograph and SD-OCT scans of the macula

Major and Lesser toxicity factors as AAO 2017

Ophthalmology further screening

Nil

Nil

After 5 years if low risk (earlier based on age) or annual if high risk

At 5 years

At 5 years

At 5 years or cumulative dose of 1000 g of hydroxychloro -quine

After 5 years if low risk (earlier based on age) or annual if presence of major risk

After 5 years if low risk (earlier based on age) or annual if presence of major risk

Important tools for screening

VA and Amsler Test

VA and Amsler Test

VA, Amsler Chart and/or HVF 10-2

Multi focal ERG is still in investigation

VA and Amsler Chart

Fundus photography.

Amsler Chart (red on black)

Suggested OCT, FAF imaging and visual electrophysiological tests

HVF 10-2 with white target

Suggested SD-OCT,

FAF and/or multi focal ERG

SD-OCT and

HVF (10-2 for Caucasian and 24-2 or 30-2 for Asian)

SD-OCT, widefield FAF and HVF 10-2

HVF 30-2 if abnormal FAF

HVF defect with normal SD-OCT and FAF require multi focal ERG

Not recommended for screening

Nil

Nil

Nil

Nil

Nil

Fundus Photography, Time Domain OCT, Fluorescein angiograph, Full field ERG, Amsler grid, Colour testing and EOG

Fundus Photography, Time Domain OCT, Fluorescein angiography, Full field ERG, Amsler grid, Colour testing and EOG

VA, Fundus Photography, Time Domain OCT, Fluorescein angiography, Full field ERG, Amsler grid, Colour testing and EOG

Long term follow-up

No further ophthalmic

examination is necessary unless the patient becomes symptomatic

Individual arrangements after 5 years

None for low risk,

Annual for high risk

May not be required in patients taking low (6.5 mg/kg) doses of hydroxychloro -quine

Most patient does not require follow-ups after check at 5 years

Annual screening in all patient after 5 years

Annual screening in all patient after 5 years

Annual screening in all patient after 5 years

[i] RCOphth: Royal College of Ophthalmologists; AAO: American Academy of Ophthalmology; HVF: Humphrey visual field; ERG: Electro-retinogram; EOG: Electro-oculogram; VA: Visual Acuity; SD-OCT: Spectral Domain Optical Coherence Tomography; FAF: Fundus Autofluorescence; Italic words: Updated in the latest guidelines; Bold & Italic words: Removed from the latest guideline

Table 2

Demographic characteristics of patients, (n=26)

Parameters

Mean (SD)

Frequency (%)

Age

33.92 (8.75)

Gender

Male

6 (23.1%)

Female

20 (76.9%)

Race

Malay

13 (50.0%)

Chinese

5 (19.2%)

Indian

8 (30.8%)

Diagnosis

SLE

15 (57.7%)

RA

7 (26.9%)

Others

4 (15.4%)

Initial Visual Acuity*

6/6

9 (34.6%)

6/9

14 (53.8%)

6/12

3 (11.5%)

Comparing the central macular thickness and optic disc retinal nerve fiber layer thickness (RNFL) using Cirrus SD-OCT in patients with connective tissue diseases on hydroxychloroquine pre-treatment, 3 months, and 6 months post-treatment.

Comparison of mean central macular thickness and optic disc RNFL thickness were summarized in (Table 3). Generally, the macula and RNFL were thinner post-treatment. Significant thinning occurred at superior, temporal, and inferior parafoveal areas and at temporal quadrant RNFL.

Comparison of the mean central macularand optic disc retinal nerve fiber layer (RNFL) thickness using Repeated Measured ANOVA test, n=26.

Table 3

Comparison of the mean central macular and optic disc retinal nerve fiber layer (RNFL) thickness using Repeated Measured ANOVA test, n=26

Pre-treatment mean(SD)

3 months post treatment mean(SD)

6 months post treatment mean(SD)

F statistics

P value

Macula Thickness

Foveal

242.00 (23.45)

239.69 (23.57)

239.08 (24.64)

1.94

0.166

Superior Parafoveal

317.81 (14.40)

315.46 (13.76)

309.62 (21.49)

1.94

0.032*

Temporal Parafoveal

302.27 (12.87)

299.58 (14.63)

299.38 (14.94)

1.94

0.025*

Inferior Parafoveal

311.73 (15.89)

309.73 (15.95)

306.85 (20.15)

1.94

0.016*

Nasal Parafoveal

319.89 (15.62)

317.85 (16.88)

316.88 (19.58)

1.94

0.076

Superior Perifoveal

285.31 (18.11)

282.23 (16.69)

282.38 (19.79)

1.82

0.184

Temporal Perifoveal

256.85 (11.55)

255.35 (11.08)

255.19 (13.08)

1.41

0.253

Inferior Perifoveal

267.08 (15.15)

264.58 (14.60)

266.96 (16.77)

1.25

0.294

Nasal Perifoveal

300.23 (17.68)

298.35 (18.27)

297.19 (19.48)

1.89

0.162

RNFL Thickness

Superior Disc

122.38 (17.30)

120.73 (15.98)

120.38 (16.57)

1.12

0.334

Temporal Disc

70.89 (18.03)

67.92 (17.76)

68.81 (17.96)

3.42

0.041*

Inferior Disc

128.96 (20.37)

126.81 (20.12)

125.58 (20.28)

3.02

0.058

Nasal Disc

68.35 (11.63)

67.58 (12.42)

67.73 (11.41)

0.20

0.816

[i] SD: Standard Deviation; *: Statistical significance (P< 0.05)

[ii] Note: Power of the study is 0.9

Post-hoc Bonferroni correction was done to establish changes of the significant retina thinning from (Table 3) over 3 months and 6 months and is summarized in (Table 4). The inferior parafoveal area showed significant retinal thinning at 3 months and 6 months when compared with the pre-treatment group.

Table 4

Post-hoc Bonferroni correction to establish changes of the significant retina thinning from Table 4

Right Eye

Pre- treatment and 3 months

Pre-treatment and 6 months

MD (95% CI)

p-value

MD (95% CI)

p -value

Superior Parafoveal

2.35 (-0.16, 4.85)

0.071

8.19 (-2.59, 18.97)

0.187

Temporal Parafoveal

2.69 (-0.71, 6.10)

0.159

2.89 (-0.18, 5.95)

0.070

Inferior Parafoveal

2.00 (0.11, 3.89)

0.035*

4.89 (0.34, 9.43)

0.032*

Temporal Disc

2.96 (-0.37, 6.29)

0.094

2.08 (-0.79, 4.95)

0.226

[i] MD= mean difference; *: Statistical significance (P< 0.05)

Linear Regression analysis to predict future thinning in the mean optic disc RNFL and the perifoveal areas based on parafoveal thinning from (Table 4) is summarized in (Table 5). All areas showed significant findings with the mean optic disc RNFL thickness significantly affected lesser (p =0.004, r=0.302) than the perifoveal area (p =0.001, r=0.784) when compared to the parafoveal thinning. Correlation analysis (Not Shown in the table) between parafoveal thinning and the mean optic disc RNFL also showed a significant result (p =0.004, r=0.55).

Table 5

Linear Regression analysis to predict future thinning in the perifoveal areas and mean optic disc RNFL on parafoveal thinning from Table 4.

Areas

β (95% CI)

t statistic (df)

p- value

r2

Total area

0.30 (0.23, 0.37)

8.65 (24)

<0.001*

0.757

Foveal

0.27 (0.03, 0.50)

2.35 (24)

0.027*

0.188

Perifoveal

0.95 (0.74, 1.16)

9.33 (24)

<0.001*

0.784

Mean Optic Disc RNFL**

0.73 (0.26,1.19)

3.22 (24)

<0.004*

0.302

[i] *: Statistical significance (P< 0.05)

[ii] **: Mean of superior, temporal, inferior, and nasal quadrants of optic disc RNFL thickness

Discussion and Conclusion

This study showed that there were significant thinning in mean macular thickness at parafoveal superior, temporal, and inferior areas. (Table 3). These changes could be the precursor to a future localized area of photoreceptor loss noted in moderate toxicity by SD-OCT. Our timelines are much earlier than Eric Chen et al13 who showed that the perifoveal thinning can be identified by SD-OCT in patients receiving hydroxychloroquine by 2 years. Likewise, SD-OCT cross-section quantitative analysis of the macula by Pasadhika et al22 found significant thinning of mean inner retinal thickness with the usage of hydroxychloroquine as early as 6 years even before ophthalmoscopic fundus changes. However, a recent study of hydroxychloroquine among SLE patients had shown that there are insignificant retinal changes with SD-OCT over 5 years duration.23 But, over 99% of their patients take less than 5 mg/kg/day of HCQ and more than 92% prescribed a dose 250 mg/day which differs enormously in daily practice. Thus, repeated measurements of macular thickness to detect early thinning is relevant while quantitative analysis (such as HD Raster with 6mm Vertical x 9mm Horizontal scan area) would only be fruitful at a later stage.

The parafoveal inferior area showed significant retinal thinning at 3 months and 6 months after hydroxychloroquine usage (Table 4) which corresponded to the typical pattern of this toxicity and coincided with a recent large study of patients using hydroxychloroquine for less than 5 years duration.24 However, two studies had documented that the typical parafoveal distribution of toxicity is not common in Asians, who show a pericentral pattern of foveal thinning.25, 26 But this perifoveal pattern in the first study was observed in Korean patients while the second study although include East Asian, Southeast Asian, and Filipinos, the total percentage of Asian was only 18%. They also found that 76% of patients had typical parafoveal changes, while only 12% each showed a perifoveal or mixed pattern. In our study, focusing on Asian patients, we found parafoveal involvement to be the first sign of toxicity. Similarly, the latest review in Korean patients showed predominantly parafoveal and mixed patterns.27 Another study showed that Hydroxychloroquine initially involves the parafovea, but becomes diffuse across the macula as damage progresses.28 With parafoveal thinning being a typical pattern, repeat of SD-OCT prior to 5 years should be done and compared to baseline values and once there is thinning should prompt for HVF 10-2 in Asians (instead of HVF 24-2) as it has better resolution and still able to detect the perifoveal defect.

The typical parafoveal thinning could predict future thinning in other areas as shown in our study (Table 5). Among all, perifoveal area showed the highest impact as compared to fovea because fovea is protected by foveal avascular zone. Thus, repeat of SD-OCT prior to 5 years should look for new areas of thinning instead of looking for worsening of the value of the same area. Parafoveal area thinning could also influence the mean disc RNFL thickness and this new finding could be important in future studies to identify the nature of the toxicity and performing appropriate screening tests.

Our study also showed RNFL thinning (at temporal quadrant) (Table 3) in patients taking hydroxychloroquine but compared to the macula thinning we could not establish a significant change at 3 months or 6 months (Table 4). There are limited studies in this area. GY Liu et al.19 showed that there is significant retinal nerve layer thinning besides macula thinning in SLE patients with chronic hydroxychloroquine usage. Another study found the patients using hydroxychloroquine for a mean of 13.4 years had thinner mean retinal nerve fiber layers values than healthy patients.14 Interestingly, an older study found significant thinning of RNFL nasal quadrant using quantitative analysis at 5 years of usage and postulated that it because of significant retinal ganglion cell degeneration. Measurement of the macular ganglion cell-inner plexiform layer (GC-IPL) over time may establish a new link this toxicity.15

The main limitation of our study is a short time of observation as further follow-ups could show transformation into structural defects. We also cannot measure the blood hydroxychloroquine level to establish compliance as proper testing is unreliable or still in development.

The fundamental challenge in managing retinal hydroxychloroquine toxicity is the possibility of toxicity before 5 years of usage. A large population study conducted in the United Kingdom in 2018 showed excess dosing of hydroxychloroquine than the recommended ophthalmology level16 as it is quite commonly prescribed as 200mg or 400mg daily dose.17 Another study also revealed that half of the patients had weight documented before prescription but not used to determine the doses.18 Further, a safe dose of 5mg/kg real bodyweight places short, obese patients at unnecessarily increased risk for retinopathy.20 It is also not uncommon that patients may develop renal disease or experience weight loss (and a higher dose) after 1 year and these patients will probably not realize they are high risk and will go without follow-up for 4 more years.21 Meanwhile, only 86% were aware that they require eye checks after five years of hydroxychloroquine use, and even worse, 20% were not compliant.29 Also, these patients’ eye reports are likely hard to acquire after 5 years.

Addressing this challenge, SD-OCT is crucial for the detection of early hydroxychloroquine retinal toxicity. And once the toxicity was detected, and the drug withheld before RPE damage, the progression is mild and limited (Reversible toxicity).30 If the drug is continued, the area of functional disturbance expands with RPE involvement and encroach fovea and stopping the drug in this stage will not prevent further deterioration of vision (Irreversible toxicity).26 Second SD-OCT imaging performed before 5-years duration, after baseline assessment may detect potential earliest retina thinning and, once there is a thinning, other modalities such as HVF 10-2, FAF, or mfERG could be used. SD-OCT also easily available and could be a cost-effective way of screening. The future applications of OCT include OCT angiography to detect the earliest microvascular changes31 and the wide-angle mode swept source OCT(SS-OCT) for its accuracy and a wider area.32

In summary, SD-OCT could evaluate potential hydroxychloroquine retinal toxicity better, and we should perform it early and repeatedly.

Source of Funding

This work is not supported by any research grant.

Conflict of Interest

The authors declare that they have no competing interests.

Acknowledgments

We are indebted to the Rheumatological, Medical, and Dermatological departments of Hospital Raja Permaisuri Bainun contributing for the patients’ pool as well as to Dr. Siti Azrin Abdul Hamid and Liu Kien Ting from the Department of Biostatistics and Research Methodology who assisted us during proposal preparation and statistical analysis respectively.

References

1 

RA Braslow M Shiloach MS Macsai Adherence to Hydroxychloroquine Dosing Guidelines by Rheumatologists: An Electronic Medical Record-Based Study in an Integrated Health Care SystemOphthalmology201712456048

2 

DJ Browning C Lee Somatotype, the risk of hydroxychloroquine retinopathy, and safe daily dosing guidelinesClin Ophthalmol2018128118

3 

GY Liu TO Utset JT Bernard Retinal nerve fiber layer and macular thinning in systemic lupus erythematosus: an optical coherence tomography study comparing SLE and neuropsychiatric SLELupus20152411116976

4 

A Saravanan T Ahmed SAT0222 Clinical risk stratification for hydroxychloroquine prescribing in a large urban district general hospitalAnn Rheum Dis201877Suppl 2972

5 

MF Marmor U Kellner TYY Lai RB Melles WF Mieler American Academy of Ophthalmology Statement: Recommendations on screening for chloroquine and hydroxychloroquine retinopathy (2016 Revision)Ophthalmology2016123138694

6 

AM Jorge RB Melles Y Zhang N Lu SK Rai LH Young Hydroxychloroquine prescription trends and predictors for excess dosing per recent ophthalmology guidelinesArthritis Res Ther201805201133

7 

E Kan K Yakar MD Demirag M Gok Macular ganglion cell-inner plexiform layer thickness for detection of early retinal toxicity of hydroxychloroquineInt Ophthalmol2018384163540

8 

HF Çay MK Erol DT Çoban M Bulut İ Sezer T Çakir Retinotoxicity of Hydroxychloroquine: Is It Possible to Demonstrate by Spectral Domain Optical Coherence Tomography Before Development? A Cross Sectional InvestigationArch Rheumatol201429317885

9 

MP Hage MR Al-Badri ST Azar A favorable effect of hydroxychloroquine on glucose and lipid metabolism beyond its anti-inflammatory roleTher Adv Endocrinol Metab2014547785

10 

TS Sharma MCM Wasko X Tang D Vedamurthy X Yan J Cote Hydroxychloroquine Use Is Associated With Decreased Incident Cardiovascular Events in Rheumatoid Arthritis PatientsJ Am Heart Assoc201651e0028670.1161/JAHA.115.002867

11 

G Manic F Obrist G Kroemer I Vitale L Galluzzi Chloroquine and hydroxychloroquine for cancer therapyMol Cell Oncol201411e29911

12 

X Yao F Ye M Zhang C Cui B Huang P Niu In Vitro Antiviral Activity and Projection of Optimized Dosing Design of Hydroxychloroquine for the Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)Clin Infect Dis20207115732910.1093/cid/ciaa237.

13 

RB Melles MF Marmor The risk of toxic retinopathy in patients on long-term hydroxychloroquine therapyJAMA Ophthalmol201413212145360

14 

C Xu L Zhu T Chan X Lu W Shen M C Madigan Chloroquine and Hydroxychloroquine Are Novel Inhibitors of Human Organic Anion Transporting Polypeptide 1A2J Pharm Sci2016105288490

15 

AR Rosenthal H Kolb D Bergsma D Huxsoll JL Hopkins Chloroquine retinopathy in the rhesus monkeyInvest Ophthalmol Vis Sci19781712115875

16 

AG Karpik MM Schwartz LE Dickey BW Streeten JL Roberts Ocular immune reactants in patients dying with systemic lupus erythematosusClin Immunol Immunopathol1985353295312

17 

NF Shroyer RA Lewis JR Lupski Analysis of the ABCR (ABCA4) gene in 4-aminoquinoline retinopathy: is retinal toxicity by chloroquine and hydroxychloroquine related to Stargardt disease?Am J Ophthalmol200113167616

18 

JY Lee N Vinayagamoorthy K Han SK Kwok JH Ju KS Park Association of Polymorphisms of Cytochrome P450 2D6 With Blood Hydroxychloroquine Levels in Patients With Systemic Lupus ErythematosusArthritis Rheumatol201668118490

19 

JA Rodriguez-Padilla TR Hedges B Monson V Srinivasan M Wojtkowski E Reichel High-speed ultra-high-resolution optical coherence tomography findings in hydroxychloroquine retinopathyArch Ophthalmol2007125677580

20 

MF Marmor Comparison of Screening Procedures in Hydroxychloroquine ToxicityArch Ophthalmol201213044619

21 

E Chen DM Brown MS Benz RH Fish TP Wong RY Kim Spectral domain optical coherence tomography as an effective screening test for hydroxychloroquine retinopathy (the “flying saucer” sign)Clin Ophthalmol (Auckland, NZ)2010411518

22 

S Pasadhika GA Fishman Effects of chronic exposure to hydroxychloroquine or chloroquine on inner retinal structuresEye (Lond)20102423406

23 

D Martín-Iglesias J Artaraz A Fonollosa A Ugarte A Arteagabeitia G Ruiz-Irastorza Evolution of retinal changes measured by optical coherence tomography in the assessment of hydroxychloroquine ocular safety in patients with systemic lupus erythematosusLupus20192845559

24 

P Gil A Nunes C Farinha D Teixeira I Pires R Silva Structural and Functional Characterization of the Retinal Effects of Hydroxychloroquine Treatment in Healthy EyesOphthalmologica2019241422633

25 

RB Melles MF Marmor Pericentral retinopathy and racial differences in hydroxychloroquine toxicityOphthalmology201512211106

26 

DH Lee RB Melles SG Joe JY Lee JG Kim CK Lee Pericentral hydroxychloroquine retinopathy in Korean patientsOphthalmology2015122612526

27 

D Eo MG Lee DI Ham SW Kang J Lee HS Cha Frequency and Clinical Characteristics of Hydroxychloroquine Retinopathy in Korean Patients with Rheumatologic DiseasesJ Korean Med Sci20173235227

28 

L De Sisternes J Hu DL Rubin MF Marmor Localization of damage in progressive hydroxychloroquine retinopathy on and off the drug: inner versus outer retina, parafovea versus peripheral foveaInvest Ophthalmol Vis Sci2015565341526

29 

K Sunmboye S Shaffu M Mccartney PS6:113 Long-term hydroxychloroquine use: are lupus patients undermonitored?: a university teaching hospital experienceLupus Sci Med20185Suppl 192

30 

MF Marmor J Hu Effect of disease stage on progression of hydroxychloroquine retinopathyJAMA Ophthalmol20141329110512

31 

M Bulut M Akıdan O Gözkaya MK Erol A Cengiz HF Çay Optical coherence tomography angiography for screening of hydroxychloroquine-induced retinal alterationsGraefes Arch Clin Exp Ophthalmol201825611207581

32 

SJ Ahn J Joung BR Lee En Face Optical Coherence Tomography Imaging of the Photoreceptor Layers in Hydroxychloroquine RetinopathyAm J Ophthalmol20191997181



jats-html.xsl

© This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.


Article type

Review Article


Article page

457-465


Authors Details

Logandran Vijaya Kumar*, Kursiah Mohd Razali, Wan Hazabbah Wan Hitam


Article History

Received : 14-03-2021

Accepted : 26-04-2021

Available online : 30-09-2021


Article Metrics


View Article As

 


Downlaod Files

   








Wiki in hindi